Behringwerke Aktiengesellschaft

Octapharma Ag

Hoechst Aktiengesellschaft

Kerckhoff-klinik Gmbh

Horst Schwinn

Norbert Heimburger

Gerhardt Kumpe

Monika Stadler

Bernd Herchenhan

Heiner Trobisch

Lothar Biesert

Wolfgang Marguerre

Djuro Josic

Werner Gehringer

Wilfried Wormsbacher

Axel Sieber

Hans M Preis

Helmut Heber

Manfred Schick

Gert Muller-Berghaus

Bernd Potzsch

Frederic Bal

Gerhard Kumpe

Heinz H Drescher

A method for the inactivation of viruses, in particular those having no lipid coats, in protein-containing compositions from blood, blood plasma or similar natural sources by treating said source, simultaneously or succesively, with an effective amount of dialkyl or trialkyl phosphates and optionally surfactants at an elevated temperature in the range of from 55&deg; C. to 67&deg; C. for five hours to 30 hours.

Method for the inactivation of non-lipid-coated viruses

Method for the affinity-chromatographic purification of factor VIII

A method for reduction of the viral infectiousness of potentially infectious material, such as human or animal body fluids or fractions derived therefrom from which biologically active substances can be isolated, wherein the infectiousness is due to non-lipid-coated viruses characterized in that

Method for reduction of the infectiousness of potentially infectious

Process for recovering a high-purity virus-inactivated factor VIII by

A stable, injectable solution containing factor VIII suitable for the treatment of humans, natural or synthetic disaccharides, preferably saccharose, in concentrations of from 0.1 to 0.65 mol/1, and one or more amino acids in concentrations of from 0.1 to 1.0 mol/1. A process for preparing same and the use of natural or synthetic disaccharides, preferably saccharose, and one or more amino acids for stabilizing factor VIII.

Stable injectable solution of factor VIII

What is disclosed is a method for isolating the cold insoluble globulin (CIG) from blood plasma concentrates containing factor VIII.

Process for the manufacture of the cold insoluble globulin and

What is disclosed is a process for rendering plasminogen virtually free of hepatitis virus by heating a plasminogen solution in the presence of a proteinase inhibitor with plasmin specificity, an amino acid, and a saccharide or sugar alcohol.

Process for the preparation of plasminogen and plasminogen thus prepared

A process for purifying liquids containing blood clotting factors by adsorption of the factors on mineral adsorbents such as calcium phosphate, aluminum hydroxide gel, barium sulfate or hydroxylapatite in the presence of calcium ions followed by elution is described.

Process for the purification of the blood clotting factors, II, VII, IX

What is disclosed is a method for making a preparation containing blood clotting Factors IX and/or X virtually hepatitis-safe by warming said peparation in the presence of calcium ions and in the further presence of an amino acid and/or a saccharide or sugar alcohol.

Method for rendering factors IX and X hepatitis-safe with calcium ions

What is disclosed is a method for treating a preparation containing blood clotting Factors II and/or VII to render it virtually hepatitis-free by warming said preparation in the presence of a chelating agent and in the further presence of an amino acid and/or a saccharide or sugar alcohol.

Method for rendering factors II and VII hepatitis-safe with a chelating

A process for stabilizing the coagulation factors II, VIII, XIII, antithrombin III and plasminogen against heat is described. The preparations obtained according to this process are practically free from coagulable fibrinogen.

Blood coagulation factors and process for their manufacture

The invention relates to an antihemophilic agent, which may contain factor VIII, but also factor IV, VII and X activities and to a process for its manufacture by extracting placentae with an aqueous hypotonic medium, increasing the density of the extract and obtaining the supernatant layer forming thereupon.

Antihemophilic agent and process for its manufacture

Lyophilized blood plasma under a protective gas wherein the protective gas contains at least 5% of carbon dioxide.

Stable blood plasma, process for preparing it and its use as comparative

A diagnostic agent containing thromboplastin sensitive to factor VII and factor X for measuring the coagulability of blood is prepared by extracting an aqueous suspension of thrombogenic tissue at pH 10 to 12, acidifying the extract, separating the extract from the tissue and adding a water-soluble calcium salt to the extract. The agent can be stabilized by adding to the extract cholanic acid and a water-soluble heavy metal-II-salt.

Growing community of inventors

Marburg, Germany

Horst Schwinn